ASTELLAS PHARMA INC. Astellas Pharma Inc. LEO Pharma A/S
Tokyo, Japan and Ballerup, Denmark, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and LEO Pharma A/S (President and CEO: Gitte P. Aabo, "LEO Pharma") today announced that the two companies completed the relevant closing conditions on March 31, 2016 to allow the transfer of the Astellas' global dermatology business to LEO Pharma from 0 a.m. on April 1.
On November 11, 2015, Astellas and LEO Pharma entered into an Asset Purchase Agreement with regard to Astellas' global portfolio of dermatology products, which includes the eczema treatment Protopic® (except for in Japan1), and other products for the treatment of acne and skin infections.
Astellas and LEO Pharma have now satisfied the pre-agreed conditions to close the transaction, with Astellas having received €675 million as a result. Astellas and LEO Pharma will continue to work closely together with the aim of securing an effective transition with continued supply to patients.
Astellas expects an immaterial impact of this closing of transaction on its financial forecasts for the fiscal year ending March 31, 2016.
1) The distribution right of Protopic® in Japan was transferred to Maruho Co. Ltd. on April 1, 2014.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new
technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide. For more information, visit www.leo-pharma.com
###
Contacts:
Astellas Pharma Inc.Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
http://www.astellas.com/en
LEO Pharma A/S Global Communications Maia Fredtoft Søchting TEL: +45 3119 3559
Astellas Pharma Inc. issued this content on 01 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 01 April 2016 00:12:19 UTC
Original Document: http://www.astellas.com/en/corporate/news/pdf/160401_Eg_1.pdf
